科兴生物制药股份有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Kexing Biopharm's Albumin-bound Paclitaxel Granted EU Market Approval 2024-07-31 18:33
Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone 2024-05-30 17:09
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound) 2024-05-10 20:07
R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm 2024-04-10 11:41
Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio 2024-01-05 19:44
Kexing Biopharm Attended CPHI Worldwide 2023 2023-11-07 20:09
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets 2023-10-09 19:09
"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" 2023-09-25 15:31
Kexing Biopharm Makes it into China's Top 20 Biopharmaceutical Enterprises (Blood Products, Vaccines and Insulin) for Two Consecutive Years 2023-07-07 19:43
Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises" 2022-07-21 22:32
1